Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 20279 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,434 million-2.2%
Operating profit¥192 million+19.3%
Ordinary income¥189 million+27.3%
Net income¥110 million-49.4%
Operating profit margin13.4 %
Selling, general and administrative expensesThe control of selling, general and administrative expenses contributed to the increase in operating income. Amount and SG&A ratio to net sales: not disclosed
Results for the three months of the current quarterNet sales: ¥1,434 million; operating income: ¥192 million; ordinary income: ¥189 million; net income attributable to owners of the parent: ¥110 million
Full-year earnings forecast
Net Sales
¥6,000 million
Operating profit
¥500 million
Ordinary income
¥480 million
Profit attributable to owners of the parent
¥330 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales23.9 %
Operating profit38.6 %
Ordinary income39.4 %
Profit attributable to owners of the parent33.5 %
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
Year-on-year change
¥-31 million
Factors
- Sluggish orders for writing instrument-related products
- Recovery in cosmetic pen tips
- Steady performance of liquid applicators
Operating profit
Year-on-year change
¥31 million
Factors
- Growth in high-value-added products in the Techno Products business
- Control of selling, general and administrative expenses
New initiatives
- Strengthen the development of high-value-added products
- Develop and expand sales of products that reduce environmental impact
- Human Capital Investment
- Strengthen sales in high-growth areas
- Factory renovations and the planned construction of a new factory to increase production capacity
Segment results
Techno Products Business
Net Sales
¥1,017 million-2.4%
Segment profit
¥222 million+9.2%
Medical Products Business
Net Sales
¥416 million-1.6%
Segment profit
¥35 million-0.9%
Medium-term management plan targets
Net Sales
¥70 million
Target fiscal yearFY2027/143rd fiscal year
Operating profit
¥10 million
Target fiscal yearFY2027/143rd fiscal year
Operating profit margin
14.3 %
Target fiscal yearFY2027/143rd fiscal year
ROE
9% or more
Target fiscal yearFY2027/143rd fiscal year
Capital Expenditure
¥15 100 million or more
PeriodTotal for the three-year medium-term plan period
Financial targets
ROE
Target9% or more
140th fiscal period results8.9％
Equity ratio
Actual results70.5 %
Market Size / Share
The presentation states that the company holds a high share of the global market, but the figure is Not disclosedNumber of employees
353 People consolidated
as_of31 March 2026
Annual Dividend
¥35 per share
Payout ratio
28.9 %
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥1,434 million (YoY -2.2%) |
| Operating profit | ¥192 million (YoY +19.3%) |
| Ordinary income | ¥189 million (YoY +27.3%) |
| Net income | ¥110 million (YoY -49.4%) |
| Operating profit margin | 13.4 % |
| Selling, general and administrative expenses | The control of selling, general and administrative expenses contributed to the increase in operating income. Amount and SG&A ratio to net sales: not disclosed |
| Results for the three months of the current quarter | Net sales: ¥1,434 million; operating income: ¥192 million; ordinary income: ¥189 million; net income attributable to owners of the parent: ¥110 million |
| Full-year earnings forecast | Net Sales ¥6,000 million / Operating profit ¥500 million / Ordinary income ¥480 million / Profit attributable to owners of the parent ¥330 million |
| Progress against full-year forecast | Net Sales 23.9 % / Operating profit 38.6 % / Ordinary income 39.4 % / Profit attributable to owners of the parent 33.5 % |
| Segment results | Techno Products Business Net Sales ¥1,017 million (YoY -2.4%) / Segment profit ¥222 million (YoY +9.2%) / Medical Products Business Net Sales ¥416 million (YoY -1.6%) / Segment profit ¥35 million (YoY -0.9%) |
| Breakdown of Factors Affecting the Change | Net Sales Year-on-year change ¥-31 million / Factors Sluggish orders for writing instrument-related products, Recovery in cosmetic pen tips, Steady performance of liquid applicators / Operating profit Year-on-year change ¥31 million / Factors Growth in high-value-added products in the Techno Products business, Control of selling, general and administrative expenses |
| Number of employees | 353 People (consolidated) |
| Medium-term management plan targets | Net Sales ¥70 million / Operating profit ¥10 million / Operating profit margin 14.3 % / ROE 9% or more / Capital Expenditure ¥15 100 million or more |
| Financial targets | ROE Target 9% or more / 140th fiscal period results 8.9％ / Equity ratio Actual results 70.5 % |
| Annual Dividend | ¥35 per share |
| Payout ratio | 28.9 % |
| Market Size / Share | The presentation states that the company holds a high share of the global market, but the figure is Not disclosed |
| New initiatives | Strengthen the development of high-value-added products, Develop and expand sales of products that reduce environmental impact, Human Capital Investment, Strengthen sales in high-growth areas, Factory renovations and the planned construction of a new factory to increase production capacity |
Items this document does not state (11)
Gross Profit MarginSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales declined slightly in both the Techno Products and Medical Products businesses. Operating income increased due to growth in high-value-added products in the Techno Products business and the control of selling, general and administrative expenses. Net income declined due to higher income tax expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.